Shaping Microbiome R&D's Future: Is Big Pharma Missing The Boat?

 
• By Donna Young
  
Generate a summary of this article
Listen to this article
Beta

The White House said the Obama administration plans to spend $121m under a new initiative to push the science of the microbiome forward. But few drug makers were among those who responded to the administration's call to action to support the initiative's overarching goals.

SC1605_NMI_1200

While the White House was all about the microbiome on May 13 in announcing a new initiative, in which President Barack Obama pledged to spend $121m over the remainder of this fiscal year and throughout the next – although he's still got to secure Congress' backing for FY 2017's appropriations – only a few drug makers were counted among the list of corporations, academic institutions and other organizations that have pledged to support R&D efforts in that area.

Indeed, so far, only two big pharmas responded to the White House's national call...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip